Co-expression of different subunits of human phenylalanine hydroxylase: Evidence of negative interallelic complementation  by Leandro, João et al.
1762 (2006) 544–550
http://www.elsevier.com/locate/bbaBiochimica et Biophysica ActaCo-expression of different subunits of human phenylalanine hydroxylase:
Evidence of negative interallelic complementation
João Leandro, Cátia Nascimento, Isabel Tavares de Almeida, Paula Leandro ⁎
Unidade de Biologia Molecular e Biopatologia Experimental, Centro de Patogénese Molecular, Faculdade de Farmácia da Universidade de Lisboa,
Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
Received 28 November 2005; received in revised form 1 February 2006; accepted 3 February 2006
Available online 28 February 2006Abstract
To study the interaction between two different subunits of the heteromeric human phenylalanine hydroxylase (hPAH), present in
hyperphenylalaninemic (HPA) compound heterozygous patients, heteroallelic hPAH enzymes were produced. A dual vector expression system
was used (PRO™ Bacterial Expression System) in which each mutant subunit was expressed from a separate compatible vector, with different
epitope tags, in a single bacterial host. Experimental conditions were selected in order that each plasmid produced equivalent levels of mutant
subunits. In this study, we demonstrated that both subunits were expressed and that the purified heteroallelic enzymes, were catalytically active. As
expected, the produced proteins displayed enzymatic activities levels lower than the predicted catalytic activity, calculated by averaging in vitro
PAH activities from both alleles, and were strongly dependent on the proteins subunit composition. The obtained data suggest that interactions
between the studied hPAH subunits, namely the I65T, R261Q, R270K and V388M, and the wild-type protein occurred. As postulated, this
phenomenon could be a source of phenotypic variation in genetic diseases involving multimeric proteins.
© 2006 Elsevier B.V. All rights reserved.Keywords: Heteroallelic human phenylalanine hydroxylase; Dual expression system; Interallelic complementation1. Introduction
Human phenylalanine hydroxylase (hPAH; E.C. 1.14.16.1)
is a homotetrameric non-heme iron dependent enzyme that
hydroxylates phenylalanine (L-Phe) to tyrosine (L-Tyr). In man,
hPAH dysfunction leads to phenylketonuria (PKU; OMIM
261600) and related forms of hyperphenylalaninemia (HPA)
[1]. The enzymatic phenotype of this recessive metabolic
disease results from the combined expression of the two mutant
alleles. Most HPA patients are heteroallelic for PAH mutations
being classified as compound heterozygous [2].
There is now considerable direct evidence indicating that it
is possible to establish genotype/phenotype correlations [3,4]
in the homoallelic state and in most cases of functional
hemizygous patients (resulting from the combination with a
“null” allele that completely abolishes PAH activity) [5].⁎ Corresponding author. Tel.: +351 217946400; fax: +351 217946491.
E-mail address: aleandro@ff.ul.pt (P. Leandro).
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doi:10.1016/j.bbadis.2006.02.001However, in the heteroallelic state inconsistencies exist
between the observed metabolic phenotype and the “predicted
residual activity” (PRA) [6], as calculated from the mean of
the monoallelic in vitro PAH enzyme activities for each
mutation comprising the genotype [3]. In these patients, the
presence of several mutations, namely the I65T, R261Q and
V388M mutations, associated either among each other or with
other mutations gives rise to more severe phenotypes than
those anticipated by the PRA [6]. This phenomenon was
already known since 1975 when Kaufman and Max [7]
observed, in parents of PKU patients (obligate heterozygous),
a deviation from proportionality in the determined PAH
activity. These authors introduced the term negative interal-
lelic complementation to illustrate the protein–protein inter-
actions occurring between the subunits of the multimeric
hPAH enzyme.
Recently, using a yeast two-hybrid approach [8,9], it was
demonstrated that the wild-type hPAH subunits interact with
different hPAH mutant subunits, thus, indicating the production
of heteromeric PAH enzymes. However, a central question
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produced hybrid hPAH proteins. Till now, the use of
conventional expression systems had never allowed to test for
the hypothesis of a negative impact of a particular mutation on
the activity of a heteromeric hPAH, since in these systems, a
single mutant allele is expressed, thus, producing a homoallelic
protein phenotype.
Using a dual vector expression strategy, for the co-
production of two mutant hPAH subunits, we were able to
mimic the natural heteroallelic state occurring in heterozygous
individuals and compound heterozygous patients. Two different
subunits were simultaneously produced in equivalent amounts
in the same bacterial host, using two different plasmids (PRO™
Bacterial Expression System). The studied mutations included
the I65T, R261Q, R270K and V388M mutant forms, which
contribute mostly for the observed genotype/phenotype incon-
sistencies in the Portuguese PKU population [10].
The determined enzymatic activities showed that when co-
expressed the produced mutant enzymes presented lower
catalytic activities than the predicted by individual expression
of the mutant subunits. The obtained results were in full
accordance with the postulated phenomenon of negative
interallelic complementation.
2. Material and methods
2.1. Materials
The PRO™ Bacterial Expression System was from Clontech (Clontech
Laboratories, Palo Alto, USA). The synthetic cofactor 6-methyl-tetrahydropterin
(6-MPH4), L-Phe, HEPES and dithiothreitol (DTT) were from Sigma Chemical
Co (St. Louis, USA). Catalase was purchased from Roche Diagnostics GmbH
(Mannheim, Germany). All reagents were of analytical grade.
2.2. Construction of recombinant dual expression vectors
The PRO™ Bacterial Expression System comprises two expression
vectors developed by Lutz and Bujard [11], namely the pPROLar and
pPROTet. These vectors present different replication origins, a Myc epitope
(–Glu–Gln–Lys–Leu–Ile–Ser–Glu–Glu–Asp–Leu–) and encode resistance
to different antibiotics such that only cells expressing both vectors would be
resistant to both kanamycin (pPROLar) and chloramphenicol (pPROTet).
The pPROLar vector contains the Plac/ara-1 promoter, induced by
isopropylthio-β-D-galactoside (IPTG) and arabinose (Ara), and the pPROTet
vector includes the PLtetO-1 promoter, induced in response to anhydrote-Table 1
Oligonucleotides used for site directed mutagenesis
Primers Position a Sequence (5′
6xHis–tag F pPROTet 96–131; pROLar 122–158 AGAAAGGT
6xHis–tagR GCTGATCA
I65T-F cDNA 183–203 CTAGATTC
I65T-R CCTGACCC
R261Q-F cDNA 772–792 GTGGAAGA
R261-R CTGGCCTT
V388M-F cDNA 1152–1172 CTCTCTGC
V388M-R CCTGTATTA
R270K-F cDNA 799–819 CAGTACAT
R270K-R GGATCCAT
a Nucleotide positions refer to Konecki-Kwok PAH cDNA (PAH Mutation Anal
positions are underlined.tracycline (aTc). A recombinant-deficient host (DH5αPRO; Clontech
Laboratories, Palo Alto, USA) was used to minimize recombination
between plasmids.
The original vectors were subjected to Site Directed Mutagenesis
(Quikchange II; Stratagene, La Jolla, USA) in order to introduce a 6xHis
purification tag (Table 1). Moreover, the pPROLar Myc-tag was removed and
the Xpress epitope (–Asp–Leu–Tyr–Asp–Asp–Asp–Asp–Lys–) was intro-
duced. The pPROLar–XPress–His and pPROTet–Myc–His expression vectors
were obtained. The enterokinase (EK) recognition sequence was maintained just
before the hPAH coding sequence in order to be possible to remove the 6xHis
tag. However, the EK treatment it is not necessary, since we have demonstrated
previously that these tags did not interfere with the activity of the recombinant
protein [12].
For prokaryotic expression the coding sequence of hPAH [13] (GenBank
accession U49897) was introduced in the BamHI site of pPROLar–XPress–His
and pPROTet–Myc–His expression vectors, in frame with the start codon.
Using the mutagenic oligonucleotides described in Table 1, the studied
mutations were introduced by Site Directed Mutagenesis (Quikchange II).
The obtained constructs were sequenced to confirm the introduction of the
desired modifications and were used to transform competent DH5αPRO cells.
Propagation of pPROTet–Myc–His constructs was performed in LB plates
supplemented with spectinomycin (50 μg/ml, final concentration) and
chloramphenicol (34 μg/ml, final concentration). The pPROLar–XPress–His
constructs were propagated in LB plates supplemented with spectinomycin and
kanamycin (both at 50 μg/ml, final concentration).
The strategy to achieve dual vector expression was to transform E. coli host
cells simultaneously with two different hPAH subunits, each cloned in a
different vector. To select the co-expressed constructs, LB plates supplemented
with spectinomycin, kanamycin (both at 50 μg/ml final concentration) and
chloramphenicol (34 μg/ml, final concentration) were used.
2.3. Co-expression of recombinant hPAH subunits
The protein expression was initially optimised, for each system individually,
by testing the optimal inducers concentration and induction time. Final
concentrations of aTc from 1 to 100 ng/ml were used for induction of
pPROTet–Myc–His constructs. The pPROLar–XPress –His constructs were
assayed for induction with a constant IPTG concentration (1 mM) and variable
amounts of arabinose in the culture medium (0 to 0.2%). Kinetic induction
studies were performed with an incubation period of 12 hours, with samples
collected at 0, 1, 2, 3, 4, 5 and 12 hours after induction.
For the co-production of two different 6xHis–hPAH subunits, fresh
overnight cultures were diluted 1:100 in LB medium containing 34 μg/ml of
chloramphenicol, 50 μg/ml of spectinomycin and 50 μg/ml of kanamycin. Cells
were grown at 37 °C with expression induced by addition of the optimised
amounts of IPTG, arabinose and aTc when the A600 was about 0.6.
Simultaneously 0.1 mM ferrous ammonium sulfate (Fe2+) was added to the
culture. Induction was performed for a period determined to maximize the
prokaryotic expression of the heteroallelic hPAH enzyme forms under
investigation.–3′)
ACCCATGGGTCATCATCATCATCATCATGAACAGAAACTGATCAGC
GTTTCTGTTCATGATGATGATGATGATGATGACCCATGGGTACCTTTCT
AGTGTGGGTCAGG
ACACTGAATCTAG
CTTGGAAGGCCAG
CCAAGTCTTCCAC
CATGTAATACAGG
CATGGCAGAGAG
GAAACATGGATCC
GTTTGATGTACTG
ysis Consortium Database; http://www.mcgill.ca/pahdb). Nucleotide mismatch
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4 °C. The pellets (stored at −20 °C until used) were resuspended (40%, w/v) in
lysis buffer (50 mM potassium phosphate; 300 mMNaCl, pH 7.8; 10% glycerol)
containing 1 mM phenylmethanesulphonyl fluoride (PMSF) and 1 mg/ml
lysozyme. After a 30 min incubation at 4 °C, cells were disrupted by passage
through a Carver Press (Model C, from F.S. Carver Inc., Wabash, IN, USA) at
4000 psi. The crude extract was then centrifuged at 10,000×g at 4 °C for 20 min.
The concentrations of imidazole and β-mercaptoethanol (β-ME) in the
supernatants were adjusted to 10 mM and processed immediately.
The recombinant 6xHis–hPAH proteins expressed from the pPROLar–
XPress–His and pPROTet–Myc–His vectors were designated 6xHis–hPAHLar
and 6xHis–hPAHTet, respectively. Expression of heteroallelic proteins was
always carried out with both possible combinations (e.g. wtLar/V388MTet and
wtTet/V388MLar).
2.4. Purification and analysis of recombinant proteins
The presence of the 6xHis tag allowed the purification of the recombinant
protein by IMAC using a Ni-chelating resin (Ni-NTA-Resin; Qiagen, Valencia,
USA), as previously described [12]. Aliquots of the purified enzyme samples
were analysed by SDS-PAGE (10% gel) after Coomassie brilliant blue R
staining. Western immuno-analysis was performed according to standard
methods [14] using the anti-Myc or the anti-Xpress as the primary antibodies
(Invitrogen; Carlsbad, USA) and the anti-mouse IgG-HRP (Cell Signalling;
Beverly, USA) as the secondary antibody. Protein concentrations were
determined by the method of Bradford [15] using bovine serum albumin
(BSA) as standard. Protein purity was assessed by densitometric scanning of
destained gels or membrane blots followed by analysis using the Gel-Pro
Analyzer (version 2.0) software (Media Cybernetics).
2.5. Assay of enzymatic activity
Enzyme assays were performed with the purified fusion proteins, essentially
as described by Martinez et al [16] with some minor modifications [12]. The
PAH activity was assayed using the synthetic cofactor 6-methyl-tetrahydropterin
(6-MPH4) and the substrate (L-Phe) at final concentrations of 500 μM and
1 mM, respectively. All stages of protein purification, analysis and enzyme
assays were performed without intervening freeze–thaw cycles.
2.6. Cleavage of the fusion peptide
The leader fusion peptide 6xHis was excised from the recombinant fusion
protein by cleavage with EK (Invitrogen, Carlsbad, USA). In this assay 50 μg of
purified enzyme were incubated with 1 U of EK in 50 mM Tris–HCl pH 8.0,
1 mM CaCl2 (ratio EK: fusion protein about 1:30) for 5 h at 4 °C.Fig. 1. Regulation of wild-type 6xHis–hPAH expression from the PLtetO-1 (A)
and PLac/ara-1 (B) promoters. Assays were performed with 500 ml of growth
medium and 4-h incubation. Each value represents the mean of two independent
analysis. Arabinose induction was performed with a constant 1 mM IPTG
concentration.3. Results
The wild-type and mutant hPAH cDNAs were cloned into
the pPROLar–XPress–His and pPROTet–Myc–His expres-
sion vectors. Western Blot analysis of crude cell lysates
revealed the presence of a single fusion protein band with a
molecular mass of about 55 kDa. Assuming a molecular mass
of 3 kDa for the fusion peptide [12] the 52-kDa protein
corresponds to the expected full-length hPAH wild-type or
mutant forms [17,18].
Expression conditions, including inducers concentration and
induction time, were analysed in order to achieve equimolecular
levels of each subunit comprising the hPAH heteroallelic state.
Regulation of wild-type hPAH expression from the PLtetO-1 and
Plac/ara-1 promoters showed that the highest and equivalent
protein levels were reached using 100 ng/ml of aTc, for the
pPROTet–Myc–His construct, and 0.2% arabinose/1 mM IPTGfor the pPROLar–Xpress–His construct (Fig. 1). Using the
above inducers concentration maximum yields of recombinant
proteins were obtained between 4 and 5 h, for the wild-type
form and at 4 h induction for the studied mutant forms (Fig. 2).
After these time points, a decrease in the protein production was
observed. Based on these observations, a 4-h induction time was
chosen to produce the wild-type and the mutant recombinant
6xHis–hPAH proteins.
After IMAC purification the 6xHis hPAHwt protein
presented, for both expression vectors, 95% purity. Similar to
the results obtained with other expression systems [12,19] the
recombinant mutant forms showed lower purity grades, namely
75–80% for the I65T, R261Q and V388M (pPROLar–XPress–
His and pPROTet–Myc–His constructs). The R270KLar protein
was produced almost to homogeneity, whereas the R270KTet
mutant protein (Fig. 3) presented only 60% purity. In addition to
a main band of full-length hPAH (55 kDa), a minor band of
higher molecular mass was observed for the R270KTet mutant
form (Fig. 3). However, Western blot analysis showed that this
band did not represent immunoreactive hPAH protein (results
not shown).
The 6xHis fusion peptide was efficiently cleaved from the
recombinant enzymes (EK digestion), yielding a protein with a
MW of about 52 kDa (results not shown).
Fig. 2. Expression of wild-type and mutant 6xHis–hPAH enzymes encoded by
the recombinant vectors pPROTet–Myc–His (A) and pPROLar–XPress–His
(B), along time induction, using the optimized inducers concentrations. (•)
hPAH wt; (□) R261Q mutant form; (▽) I65T mutant form; (▴) V388M mutant
form; (◊) R270K mutant form. Each value represents the mean of two
independent experiments.
Fig. 4. Western blotting analysis of purified (1) 6xHis–hPAHwtTet (Myc
epitope); (2) 6xHis–hPAH V388MLar (Xpress epitope) and (3) co-produced
6xHis–hPAHwtTet/6xHis–hPAH V388MLar protein (Myc and Xpress epitope).
Immunodetection using the anti-Myc (A) and anti-Xpress (B) antibodies (see
text for details).
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by Western blot analysis of the purified recombinant proteins,
using the anti-Myc and the anti-Xpress antibodies. The presence
of the two subunits possessing both epitopes is illustrated in Fig.
4 for the co-produced 6xHis–hPAHwtTet/V388MLar.
In order to perform a comparative analysis, the enzymatic
activities of the homomeric forms of 6xHis hPAH proteins were
also determined (Table 2). When assayed at standard conditions
(1 mM L-Phe and 500 μM 6-MPH4), the wild-type form
revealed a catalytic activity of 5818 nmol Tyr min−1 mg−1. TheFig. 3. SDS-PAGE analysis of hPAH mutant forms expressed from recombinant
vectors pPROLar–XPress–His (A) and pPROTet–Myc–His (B). (M) Molecular
weight marker; (1–4) 6xHis–hPAH recombinant forms of R261Q (1); I65T (2);
V388M (3) R270K (4) and; wild-type (5).purified homomeric R270K protein exhibited only 2.1% (121
nmol Tyr min−1 mg−1) of residual activity, whereas mutations
I65T, R261Q and V388M presented 26.5% (1539 nmol Tyr
min−1 mg−1), 27.6% (1603 nmol Tyr min−1 mg−1) and 27%
(1569 nmol Tyr min−1 mg−1) respectively, of the activity of the
native enzyme.
The subunits of the co-produced 6xHis hPAH proteins were
expressed alternatively by each of the vectors and their
enzymatic activities were determined. The obtained values
were compared (Student's t test) in order to determine if their
difference were statistically significant (Table 2).
As shown in Table 2, the enzymatic activities of the purified
co-produced mutant proteins were always lower than the PRA.
The R270K/R261Q protein presented an experimental activity
21% lower than the PRA. For the V388M/I65T, V388M/R261Q
and I65T/R261Q we could observe a similar effect in the
decrease of the enzymatic activity (38, 35 and 28%, respective-
ly). Proteins produced by co-expressing the R270K and V388M
alleles showed the higher activity decrease (88%), while the
R270K/I65T co-produced protein presented an experimental
activity 52% lower than the PRA. The hPAHwt/V338M protein,
mimicking a heterozygous condition, also presented a residual
activity (38.5%) lower than the PRA (63.5%).
4. Discussion
Interallelic complementation is a phenomenon that occurs
when a hybrid protein is expressed from two different mutated
alleles of a gene. When compared to the predicted residual
activity the produced heteromeric protein could present a higher
(positive complementation) or lower (negative complementa-
tion) catalytic activity.
The observation that some PKU patients present a more
severe phenotype than the predicted [6] suggests that the
resulting heterotetrameric enzyme activity should be lower than
the predicted value, determined from the independent enzyme
activities of the respective homomeric mutant proteins. To give
an explanation for this phenomenon the occurrence of a negative
interallelic complementation mechanism has been evoked.
While interactions of different subunits of a hybrid hPAH
protein were already proven to occur [8,9], the enzymatic activi-
ties of such heteromeric proteins had never been determined.
In order to co-produce two different subunits of a
heteroallelic hPAH phenotype, a prokaryotic dual vector co-
Table 2
Enzymatic activities of homoallelic and heteroallelic 6xHis hPAH recombinant proteins produced by simultaneous expression of two subunits
PAH sub-unit composition Specific activity a
(nmol Tyr min−1 mg−1)
Residual enzyme
activity b (%)
PRAc
(%)
Observed
decrease (%)
hPAHwtLar/hPAHwtTet 5818±82.7 (100%) – –
I65TLar/I65TTet 1539±42.4 (26.5%) – –
R261QLar/R261QTet 1603±49.5 (27.6%) – –
R270KLar/R270KTet 121±18.4 (2.1%) – –
V388MLar/V388MTet 1569±41.0 (27.0%) – –
V388MLar/hPAHwtTet 2336 (40%) 38.5 63.5 39
V388MTet/hPAHwtLar 2200 (37%)
(P n.d.)
V388MLar/I65TTet 918±49.0 (15.8%) 16.5 26.7 38
V388MTet/I65TLar 1003±20.8 (17.2%)
(P>0.05)
V388MLar/R261QTet 1062±34.9 (18.2%) 17.6 27.3 35
V388MTet/R261QLar 987±35.5 (17.0%)
(P>0.05)
V388MLar/R270KTet 118±7.4 (2.03%) 1.77 14.4 88
V388MTet/R270KLar 88±15.6 (1.51%)
(P>0.05)
R270KLar/I65TTet 474±6.0 (8.15%) 6.91 14.3 52
R270KTet/I65TLar 330±10.5 (5.67%)
(P<0.001)
R270KLar/R261QTet 676±10.5 (11.6%) 11.8 14.8 21
R270KTet/R261QLar 691±8.3 (11.9%)
(P>0.1)
I65TLar/R261QTet 1185±15.9 (20.4%) 19.4 27.0 28
I65TTet/R261QLar 1075±20.5 (18.5%)
(P<0.01)
a Values are means ± standard deviation determined from three independent experiments, except for the V388MLar/hPAHwtTet and V388MTet/hPAHwtLar constructs
(two experiments); Statistical analysis compared subunits produced from different expression vectors; statistical significance (P value) was determined using the
Student's t test; values in parenthesis refer to % of activity relative to the wild-type form (residual activity).
b Mean of residual enzyme activity determined for both constructs.
c (PRA) Predicted enzymatic activity, calculated by averaging the experimental enzymatic activities of the corresponding homomeric proteins. (n.d.) not
determined.
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of promoter regulation allowed us to control independently the
expression of the two cloned alleles. Actually, the use of 100 ng/
ml of aTc (pPROTet–Myc–His constructs) and 0.2% arabinose/
1 mM IPTG (pPROLar–XPress–His constructs) produced
similar quantities of each different protein (Fig. 1). This fact
represents one of the greatest advantages of the dual vector
system when compared to the bicistronic system [20].
We first studied each expression vector individually in order
to confirm that they were suitable for the production of
catalytically active PAH enzyme. The use of pPROLar–
XPress–His and pPROTet–Myc–His expression vectors
allowed the purification of the full-length recombinant
6xHis–hPAH proteins (55 kDa), with purity grades ranging
from 60 to 95%. The resulting mutant homoallelic forms
presented relative enzymatic activities (Table 2) similar to those
obtained previously, using the pTrcHis prokaryotic expression
system [12,19].
The presence of different epitopes in the constructs (Myc and
Xpress) allowed us to confirm the presence of both subunits in
the coexpressing assays. As shown by Western blot analysis
(Fig. 4), cotransformation with the different pPROLar–XPress–
His and pPROTet–Myc–His constructs into the E. coli strain
DH5αPRO resulted in the production of similar levels of thetwo different subunits of the co-produced hPAHwtTet/V388MLar
protein.
In order to prove that the determined enzymatic activities of
the co-produced proteins were independent of the vector used to
express the studied allele, each hPAH subunit, comprising the
heteroallelic state, was always synthesized in the two possible
combinations (Table 2). The obtained enzymatic activities were
not significantly different (P>0.05), except for the R270K/I65T
(P<0.001) and R261Q/I65T (P<0.01) proteins. In these two
co-produced proteins the determined P value (<0.05) could not
be explained neither by the presence of a particular subunit,
namely the I65T subunit as it was not observed for the co-
produced V388M/I65T mutant protein, nor by an higher
expression level of one of the vectors. Moreover, the same
range of residual activity was calculated (Table 2) for the
R270K/I65T combinations (8.1 and 5.67%) and for the R261Q/
I65T combinations (18.5 and 20.4%). Therefore, any of the
construct combinations could be used to study the interallelic
complementation phenomenon.
We could demonstrate for the heteroallelic mutant proteins,
a decrease in the enzymatic activity when compared to the
predicted residual activity (PRA). These values, ranging from
88% (V388M/R270K) to 21% (R270K/R261Q), reflect a
negative interaction between the studied mutant subunits.
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strongly dependent on the nature of the mutant proteins
present. Among these, the R270K subunit presented a higher
negative effect, particularly over the V388M subunit. It has
been postulated that reduced stability is likely the most
important attribute for the association of the R270K mutation
with PKU in vivo [19]. Therefore, the observed drastic effect
of this mutant subunit could be related to an altered protein
oligomerisation.
Each subunit of the tetrameric hPAH comprises a N-terminal
regulatory domain (Ser2–Ser110), a catalytic domain (Ser110–
Ser411) a dimerisation motif (Ser411–Thr427) and a C-terminal
tetramerisation domain (Glu428–Lys452) [21]. The regulatory
domain from one subunit establishes contacts with the catalytic
domain of the other subunit in the dimer. The tetramers are
considered to be a dimer of dimers in which the subunits in one
dimer contact the subunits in the adjacent dimer only via the α-
helical tetramerisation motif. As none of the studied mutations
affect the hPAH tetramerisation domain (I65T and R261Q are
dimer interface mutations) [22,23] probably they will affect the
existing interactions between the subunit interfaces and not
directly the tetrameric unit assembly. As a consequence, the
enzymatic function could be directly affected as the studied
mutations could interfere with the necessary conformational
changes occurring at the dimer interface upon activation by L-
Phe [24]. We could also admit that they result in quaternary
structures relatively less stable. In this regard, the dual
expression system described herein will allow the study of the
oligomerisation pattern of the produced proteins as well as their
enzymatic properties (studies in course). It must be noted that
albeit there is now a high-resolution structure available for the
hPAH enzyme, there is still no direct proof of subunit
interaction or a clear insight into the possible structural basis
of any such interaction.
In conclusion, from our observations, it seems clear that a
phenomenon of negative interallelic complementation exists
between the studied hPAH subunits, mimicking heterozygous
and heterozygous compound patients. Furthermore, it appears
likely that this phenomenon could be a general source of
phenotypic variation in genetic diseases involving multimeric
proteins. Such interactions must be considered in any attempt to
establish genotype/phenotype correlations in patients affected
by such disorders.
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